Novo Nordisk A/S-BNONOF
13F holders, Q2 2026 (June 30)3holders
0new positions
0sold out
$48.07avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding Novo Nordisk A/S-B (NONOF) in their 13F filings, unchanged from Q1 2026. 0 opened new positions and 0 sold out. The largest holders were Cygnus Capital Advisors, LLC ($3.8M), Generali Investments CEE, investicni spolecnost, a.s. ($1.3M) and Atlas Capital Advisors Inc. ($251K).
- Company
- Novo Nordisk A/S-B
- CUSIP
- K72807140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 24,000 shares bought and 2,920 shares sold, net +21,080 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Cygnus Capital Advisors, LLC | 2.57% | Add +43.8% | 78,800 | $3.8M |
| Generali Investments CEE, investicni spolecnost, a.s. | 0.06% | Reduce -9.6% | 27,399 | $1.3M |
| Atlas Capital Advisors Inc. | 0.03% | No change | 5,218 | $251K |
"% of holder's portfolio" is NONOF's weight in each manager's 13F, not the share of Novo Nordisk A/S-B the manager owns.